Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, has announced it will release its second quarter 2024 financial results and provide a business update on Tuesday, August 13, 2024, before the opening of U.S. financial markets. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the results.
Interested parties can register for the conference call using a provided link, which will supply a dial-in number and unique PIN. A live webcast will also be available on the company's website. Additionally, Fennec has announced its participation in the 2024 Wedbush PacGrow Healthcare Conference, taking place August 13-14, 2024, in New York, NY.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), una società farmaceutica specializzata in fase commerciale, ha annunciato che pubblicherà i propri risultati finanziari del secondo trimestre 2024 e fornirà un aggiornamento aziendale il martedì 13 agosto 2024, prima dell'apertura dei mercati finanziari statunitensi. La società ospiterà una chiamata in conferenza e un webcast alle 8:30 del mattino (ora orientale) lo stesso giorno per discutere i risultati.
Le parti interessate possono registrarsi per la chiamata in conferenza utilizzando un link fornito, che fornirà un numero di accesso e un PIN unico. Sarà anche disponibile un webcast dal vivo sul sito web dell'azienda. Inoltre, Fennec ha annunciato la propria partecipazione alla 2024 Wedbush PacGrow Healthcare Conference, che si svolgerà dal 13 al 14 agosto 2024, a New York, NY.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), una compañía farmacéutica especializada en fase comercial, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 y proporcionará una actualización empresarial el martes 13 de agosto de 2024, antes de la apertura de los mercados financieros de EE. UU. La compañía llevará a cabo una llamada de conferencia y transmisión web a las 8:30 a.m. hora del este el mismo día para discutir los resultados.
Las partes interesadas pueden registrarse para la llamada de conferencia utilizando un enlace proporcionado, que dará un número de acceso y un PIN único. También estará disponible una transmisión web en vivo en el sitio web de la compañía. Además, Fennec ha anunciado su participación en la Conferencia de Atención Médica Wedbush PacGrow 2024, que se llevará a cabo del 13 al 14 de agosto de 2024, en Nueva York, NY.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX)는 상업 단계의 전문 제약 회사로, 2024년 2분기 재무 결과를 발표하고 2024년 8월 13일 화요일에 비즈니스 업데이트를 제공할 것이라고 발표했습니다. 미국 금융 시장 개장 전에 발표됩니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 결과를 논의하기 위한 전화 회의 및 웹 세미나를 주최할 예정입니다.
관심 있는 당사자는 제공된 링크를 사용하여 전화 회의에 등록할 수 있으며, 해당 링크는 전화 번호와 고유 PIN을 제공합니다. 회사 웹사이트에서도 실시간 웹 세미나를 이용할 수 있습니다. 또한 Fennec은 2024 Wedbush PacGrow Healthcare Conference에 참여할 것이라고 발표했으며, 이 회의는 2024년 8월 13일부터 14일까지 뉴욕에서 개최됩니다.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), une entreprise pharmaceutique spécialisée en phase commerciale, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 et fournira une mise à jour commerciale le mardi 13 août 2024, avant l'ouverture des marchés financiers américains. L'entreprise organisera une conférence téléphonique et un webinaire à 8h30, heure de l'Est, le même jour pour discuter des résultats.
Les parties intéressées peuvent s'inscrire à la conférence téléphonique via un lien fourni, qui fournira un numéro d'appel et un code PIN unique. Un webinaire en direct sera également disponible sur le site Web de l'entreprise. De plus, Fennec a annoncé sa participation à la 2024 Wedbush PacGrow Healthcare Conference, qui se déroulera du 13 au 14 août 2024 à New York, NY.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), ein kommerzielle Phase spezialisiertes Pharmaunternehmen, hat angekündigt, dass es seine finanziellen Ergebnisse des zweiten Quartals 2024 veröffentlichen und am Dienstag, den 13. August 2024, bevor die US-Finanzmärkte öffnen, ein Geschäftsupdate bereitstellen wird. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu erörtern.
Interessierte Parteien können sich über einen bereitgestellten Link für die Telefonkonferenz anmelden, der eine Einwahlnummer und eine eindeutige PIN zur Verfügung stellt. Außerdem wird ein Live-Webcast auf der Unternehmenswebsite verfügbar sein. Zusätzlich hat Fennec seine Teilnahme an der 2024 Wedbush PacGrow Healthcare Conference angekündigt, die am 13. und 14. August 2024 in New York, NY, stattfinden wird.
- Scheduled release of Q2 2024 financial results indicates transparency and regular reporting
- Participation in the 2024 Wedbush PacGrow Healthcare Conference may increase visibility among investors
- None.
Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2024 financial results and provide a business update before the opening of the U.S. financial markets on Tuesday, August 13, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
Conference Call & Webcast Detail:
| Date: | Tuesday, August 13, 2024 | ||
| Time: | 8:30 a.m. Eastern Time | ||
| Link: | https://register.vevent.com/register/BI59b5706a6c00453a9eed343d4a210de9 | ||
To access the conference call, please register using https://register.vevent.com/register/BI59b5706a6c00453a9eed343d4a210de9. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennepharma.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
2024 Wedbush PacGrow Healthcare Conference Participation:
Fennec also announced that it will participate in the 2024 Wedbush PacGrow Healthcare Conference taking place August 13-14, 2024, in New York, NY.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® and Pedmarqsi to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission Marketing Authorization in June 2023 for Pedmarqsi. PEDMARK has received Orphan Drug Exclusivity in the U.S. for seven years of market protection and Pedmarqsi has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When will Fennec Pharmaceuticals (FENC) release its Q2 2024 financial results?
How can investors access Fennec Pharmaceuticals' (FENC) Q2 2024 earnings call?
What conference will Fennec Pharmaceuticals (FENC) participate in during August 2024?
